Abstract
Clinical studies have shown that pindolol can enhance the effects of antidepressant drugs, presumably by acting as an antagonist at somatodendritic 5-hydroxytryptamine (5-HT)1A autoreceptors, which regulate the firing rate of central serotonergic neurons. The current study characterized the action of pindolol on the single-unit activity of serotonergic neurons in the dorsal raphe nucleus of freely moving cats. (±)-Pindolol produced a dose-dependent inhibition of neuronal activity after i.v. (ED50 = 0.25 mg/kg) and s.c. (ED50 = 1.23 mg/kg) administration. The active enantiomer (−)-pindolol (1 mg/kg i.v.) also suppressed neuronal activity (maximal decrease, 88%). Upon p.o. administration, (±)-pindolol (10 mg/kg) produced a marked, long-acting suppression of neuronal activity similar to that observed after s.c. administration. In all cases, the reduction in firing rate produced by pindolol was completely reversed by low doses ofN-[2-[4-(2-methoxyphenyl)-1-piperazinyl]-ethyl]-N-(2-pyridinyl)cyclohexanecarboxamide (WAY-100635) (0.1 mg/kg i.v. or 0.2 mg/kg s.c.), a selective 5-HT1A antagonist. Systemic administration of (−)-tertatolol (1–5 mg/kg i.v.), another β-adrenoceptor blocker/putative 5-HT1A antagonist, had no significant effect on neuronal activity. The ability of i.v. (±)-pindolol (0.1–1 mg/kg) to reverse the suppression of serotonergic neuronal activity produced by 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) (10 μg/kg i.v.), a selective 5-HT1A agonist, also was examined. (±)-Pindolol had no appreciable effect on the action of 8-OH-DPAT. In contrast, the 5-HT1A antagonist drugs WAY-100635 (0.1 mg/kg i.v.), 4-fluoro-N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-N-2-pyridinyl benzamide (0.1 mg/kg, i.v.),N-tert-butyl-3-(4-(2-methoxyphenyl)piperazin-1-yl)-2-phenylpropanamide [(S)-WAY-100135] (0.5 mg/kg i.v.), and (−)-tertatolol (1–5 mg/kg i.v.) reversed the effect of 8-OH-DPAT to varying degrees. Overall, these results indicate that pindolol acts as an agonist rather than an antagonist at 5-HT1A autoreceptors in awake animals.
Footnotes
-
Send reprint requests to: Dr. Casimir A. Fornal, Program in Neuroscience, Department of Psychology, Green Hall, Princeton University, Princeton, NJ 08544. E-mail: Fornal{at}princeton.edu
-
↵1 This work was supported by a grant from the National Institute of Mental Health (MH-23433).
-
↵2 Recipient of a Formacion de Personal Investigador Postdoctoral Fellowship from the Spanish government. Present address: Department of Physiology and Pharmacology, School of Medicine, University of Cantabria, Santander, Cantabria, Spain.
- Abbreviations:
- 5-HT
- 5-hydroxytryptamine
- SSRI
- selective serotonin reuptake inhibitor
- DRN
- dorsal raphe nucleus
- WAY-100635
- N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-N-(2-pyridinyl)cyclohexanecarboxamide
- 8-OH-DPAT
- 8-hydroxy-2-(di-n-propylamino)tetralin
- p-MPPI
- 4-fluoro-N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-N-2-pyridinyl benzamide
- (S)-WAY-100135
- N-tert-butyl-3-(4-(2-methoxyphenyl)piperazin-1-yl)-2-phenylpropanamide
- LSD
- d-lysergic acid diethylamide
- Received March 11, 1999.
- Accepted May 25, 1999.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|